mk-4334
Mild Cognitive Impairment
Merck Sharp & Dohme LLCPhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 73/ 100
Competitive context
150 Active assets in the Mild Cognitive Impairment cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ginkgo Biloba Extract Xiyuan Hospital of China Academy of Chinese Medical Sciences | Phase 4 | BBB |
Nicotine University of Southern California | Phase 2 | BBB |
Rivastigmine Singapore General Hospital | Phase 4 | BBB |
Oxybutynin University of Alberta | Phase 4 | BBB |
Seroquel® Emory University | Phase 4 | BB |
View all 50 →
Same molecule, other indications
mk-4334 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →